Table III.
Association of clinicopathological factors and expression of PRKCA in patients with lung adenocarcinoma.
| PRKCA expression | ||||
|---|---|---|---|---|
| Factors | n | Low, n (%) | High, n (%) | P-value |
| Sex | ||||
| Male | 67 | 30 (44.8) | 37 (55.2) | 0.988 |
| Female | 56 | 25 (44.6) | 31 (55.4) | |
| Age, years | ||||
| ≤60 | 67 | 28 (41.8) | 39 (58.2) | 0.476 |
| >60 | 56 | 27 (48.2) | 29 (51.8) | |
| T classification | ||||
| T1-T2 | 103 | 51 (49.5) | 52 (50.5) | 0.015 |
| T3-T4 | 20 | 4 (20.0) | 16 (80.0) | |
| N classification | ||||
| N0-N1 | 80 | 47 (58.8) | 33 (41.3) | <0.001 |
| N2-N3 | 43 | 8 (18.6) | 35 (81.4) | |
| Lymph node metastasis | ||||
| Negative | 61 | 36 (59) | 25 (41) | 0.002 |
| Positive | 62 | 19 (30.6) | 43 (69.4) | |
| Clinical stage | ||||
| I–II | 76 | 46 (60.5) | 30 (39.5) | <0.001 |
| III–IV | 47 | 9 (19.1) | 38 (80.9) | |
PRKCA, protein kinase Cα; T, tumour; N, node.